Posts tagged Beta Drugs
Latest Research Reports On Stocks By Leading Brokerages: If you have any research reports that you would like to share with us, please send it to michael@rakesh-jhunjhunwala.in or to admin@rakesh-jhunjhunwala.in. (The pre-June 2016 reports are available here).
| Beta Drugs has delivered a healthy performance. Buy for target price of Rs 1325 (27% upside): Nuvama | |
| Company: | Beta Drugs |
| Brokerage: | Nuvama |
| Date of report: | September 3, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 27% |
| Summary: | Beta Drugs (BETADR) is one of the leading players in the domestic oncology space and ranks among the top 10 in the cytotoxic market. Equipped with three state-of-the-art manufacturing facilities, it produces and markets a wide range of oncology (anti-cancer) drugs, which are available across major government and private hospitals. It expanded, upgraded, and received regulatory approvalsfrom INVIMA (Colombia)/INVISA (Brazil) for its key facilities which will aid exports |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Nuvama |